Scout announces FDA Authorization of the UOL COVID-19 Test for Point-of-Care

Written by Jared Hsu

Feb 08, 2022 | Read time: 0 min
Scout announces FDA Authorization of the UOL COVID-19 Test for Point-of-Care

Molecular diagnostics company Uh-Oh Labs has received an emergency use authorization (EUA) from the Food and Drug Administration (FDA) for the UOL COVID-19 Test for use at the point-of-care with customers who have a CLIA Waiver, Certificate of Compliance, or Certificate of Accreditation. The UOL COVID-19 Test is a nucleic acid amplification test which allows for detection of SARS-CoV-2 RNA down to 400cp/swab within 40 minutes. In a clinical study, the UOL COVID-19 Test demonstrated a 96.1% overall agreement with an EUA authorized high-sensitivity RT-PCR assay, no false positives, and detected 97.9% of SARS-CoV-2 positive samples, excluding those with very low levels of virus.

The UOL COVID-19 Test is comprised of a reusable Instrument, disposable Test Kits, and a mobile Dx Pro iOS app. The UOL COVID-19 Test has been designed to simplify sample collection, running the assay, and result interpretation. The UOL COVID-19 Test has also been engineered specifically to lower per-test cost by leveraging the proprietary Loop-de-Loop platform. An assay can be started within 5 minutes, including sample collection and patient registration, and then runs 40 minutes “hands off”, allowing for a streamlined workflow. The results are then viewable on the Dx Pro app with plain language results, removing the need to interpret lateral flow lines.

The UOL COVID-19 Test production is already underway and available for purchase from qualified customers who have a CLIA Waiver, Certificate of Compliance, or Certificate of Accreditation. Additionally, UOL is actively working towards an EUA for the UOL COVID-19 Test for non-prescription, non-laboratory use.

Uh-Oh Labs has been supported with over $15M in contracts from the National Institutes of Health as well as investments from private investors such as Y Combinator.

View the Letter of Authorization, as well as relevant documents for the UOL COVID-19 Test, on the FDA’s website.

About UOL

Uh-Oh Labs (UOL) is a California-based diagnostics and health tech company with a mission to improve public health by developing affordable and accurate diagnostics. UOL is developing tests through the proprietary Loop-de-Loop platform which enables simplicity, speed, and lower costs while providing accurate, lab-grade results. Additionally, UOL is partnering with other members of the healthcare ecosystem to expand access of lab-grade diagnostics and improve the delivery of care. UOL has received Emergency Use Authorization for the UOL COVID-19 Test and is developing tests for other indications including flu, STIs, and diagnostic biomarkers. UOL has been funded in part by the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative, as well as funding from private investors including Y Combinator.

Heading 2 - Lorem ipsum dolor sit amet

Mi tincidunt elit, id quisque ligula ac diam, amet. Vel etiam suspendisse morbi eleifend faucibus eget vestibulum felis. Dictum quis montes, sit sit. Tellus aliquam enim urna, etiam. Mauris posuere vulputate arcu amet, vitae nisi, tellus tincidunt. At feugiat sapien varius id.

Eget quis mi enim, leo lacinia pharetra, semper. Eget in volutpat mollis at volutpat lectus velit, sed auctor. Porttitor fames arcu quis fusce augue enim. Quis at habitant diam at. Suscipit tristique risus, at donec. In turpis vel et quam imperdiet. Ipsum molestie aliquet sodales id est ac volutpat.

Image caption goes here

Heading 3 - Lorem ipsum dolor sit amet consectetur adipiscing elit sed do eiusmod tempor incididunt ut labore et dolore.

Heading 4 - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Libero volutpat sed cras ornare arcu dui vivamus arcu. Nibh praesent tristique magna sit amet purus gravida.

Heading 5 - Lorem lorem lorem
  • Test list item
  • Test list item

Elit nisi in eleifend sed nisi. Pulvinar at orci, proin imperdiet commodo consectetur convallis risus. Sed condimentum enim dignissim adipiscing faucibus consequat, urna. Viverra purus et erat auctor aliquam. Risus, volutpat vulputate posuere purus sit congue convallis aliquet. Arcu id augue ut feugiat donec porttitor neque. Mauris, neque ultricies eu vestibulum, bibendum quam lorem id. Dolor lacus, eget nunc lectus in tellus, pharetra, porttitor.

"Ipsum sit mattis nulla quam nulla. Gravida id gravida ac enim mauris id. Non pellentesque congue eget consectetur turpis. Sapien, dictum molestie sem tempor. Diam elit, orci, tincidunt aenean tempus."

Tristique odio senectus nam posuere ornare leo metus, ultricies. Blandit duis ultricies vulputate morbi feugiat cras placerat elit. Aliquam tellus lorem sed ac. Montes, sed mattis pellentesque suscipit accumsan. Cursus viverra aenean magna risus elementum faucibus molestie pellentesque. Arcu ultricies sed mauris vestibulum.

Conclusion

Morbi sed imperdiet in ipsum, adipiscing elit dui lectus. Tellus id scelerisque est ultricies ultricies. Duis est sit sed leo nisl, blandit elit sagittis. Quisque tristique consequat quam sed. Nisl at scelerisque amet nulla purus habitasse.

Nunc sed faucibus bibendum feugiat sed interdum. Ipsum egestas condimentum mi massa. In tincidunt pharetra consectetur sed duis facilisis metus. Etiam egestas in nec sed et. Quis lobortis at sit dictum eget nibh tortor commodo cursus.

Odio felis sagittis, morbi feugiat tortor vitae feugiat fusce aliquet. Nam elementum urna nisi aliquet erat dolor enim. Ornare id morbi eget ipsum. Aliquam senectus neque ut id eget consectetur dictum. Donec posuere pharetra odio consequat scelerisque et, nunc tortor.
Nulla adipiscing erat a erat. Condimentum lorem posuere gravida enim posuere cursus diam.